1177 Stock Overview
An investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
1177 passed our risk checks.
Sino Biopharmaceutical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.75 |
| 52 Week High | HK$3.89 |
| 52 Week Low | HK$2.29 |
| Beta | 0.58 |
| 1 Month Change | -11.00% |
| 3 Month Change | -12.70% |
| 1 Year Change | -25.88% |
| 3 Year Change | -63.96% |
| 5 Year Change | -47.25% |
| Change since IPO | 10,025.93% |
Recent News & Updates
Recent updates
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly
May 21
Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings
Apr 21What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates
Apr 03Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 20Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon
Dec 18Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?
Dec 02Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate
Nov 17We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease
Aug 30Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?
May 26Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet
Apr 20Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?
Feb 09Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?
Nov 11Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly
Oct 24Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?
Jul 08Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?
Apr 28An Intrinsic Calculation For Sino Biopharmaceutical Limited (HKG:1177) Suggests It's 45% Undervalued
Jan 22Sino Biopharmaceutical (HKG:1177) Has A Pretty Healthy Balance Sheet
Dec 03Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?
Oct 19Sino Biopharmaceutical (HKG:1177) Has Re-Affirmed Its Dividend Of HK$0.02
Sep 03Shareholder Returns
| 1177 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 1.1% | -2.8% | -2.3% |
| 1Y | -25.9% | -7.6% | -3.6% |
Return vs Industry: 1177 underperformed the Hong Kong Pharmaceuticals industry which returned -7.6% over the past year.
Return vs Market: 1177 underperformed the Hong Kong Market which returned -3.6% over the past year.
Price Volatility
| 1177 volatility | |
|---|---|
| 1177 Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in HK Market | 15.2% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 1177 has not had significant price volatility in the past 3 months.
Volatility Over Time: 1177's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 25,806 | Eric S. Y. Tse | www.sinobiopharm.com |
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.
Sino Biopharmaceutical Limited Fundamentals Summary
| 1177 fundamental statistics | |
|---|---|
| Market cap | HK$50.43b |
| Earnings (TTM) | HK$1.99b |
| Revenue (TTM) | HK$28.19b |
25.4x
P/E Ratio1.8x
P/S RatioIs 1177 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1177 income statement (TTM) | |
|---|---|
| Revenue | CN¥26.20b |
| Cost of Revenue | CN¥4.99b |
| Gross Profit | CN¥21.21b |
| Other Expenses | CN¥19.36b |
| Earnings | CN¥1.85b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.10 |
| Gross Margin | 80.95% |
| Net Profit Margin | 7.05% |
| Debt/Equity Ratio | 32.3% |
How did 1177 perform over the long term?
See historical performance and comparison